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We have reported previously that reactive-site mutants of
N-TIMP-3 [N-terminal inhibitory domain of TIMP-3 (tissue
inhibitor of metalloproteinases 3)] modified at the N-terminus,
selectively inhibited ADAM17 (a disintegrin and metallopro-
teinase 17) over the MMPs (matrix metalloproteinases). The
primary aggrecanases ADAMTS (ADAM with thrombospondin
motifs) -4 and -5 are ADAM17-related metalloproteinases which
are similarly inhibited by TIMP-3, but are poorly inhibited by
other TIMPs. Using a newly developed recombinant protein
substrate based on the IGD (interglobular domain) of aggrecan,
gst-IGD-flag, these reactive-site mutants were found to similarly
inhibit ADAMTS-4 and ADAMTS-5. Further mutations of N-
TIMP-3 indicated that up to two extra alanine residues can be
attached to the N-terminus before the K i (app) for ADAMTS-4
and ADAMTS-5 increased to over 100 nM. No other residues
tested at the [−1] position produced inhibitors as potent as the
alanine mutant. The mutants N-TIMP-3(T2G), [−1A]N-TIMP-
3 and [−2A]N-TIMP-3 were effective inhibitors of aggrecan
degradation, but not of collagen degradation in both IL-1α
(interleukin-1α)-stimulated porcine articular cartilage explants
and IL-1α with oncostatin M-stimulated human cartilage explants.
Molecular modelling studies indicated that the [−1A]N-TIMP-3
mutant has additional stabilizing interactions with the catalytic
domains of ADAM17, ADAMTS-4 and ADAMTS-5 that are
absent from complexes with MMPs. These observations suggest
that further mutation of the residues of N-TIMP-3 which
make unique contacts with these metalloproteinases may allow
discrimination between them.
Key words: a disintegrin and metalloproteinase with
thrombospondin motifs (ADAMTS), aggrecanase, collagenase,
metalloproteinase, osteoarthritis, tissue inhibitor of metallopro-
teinases 3 (TIMP-3).
INTRODUCTION
The TIMPs (tissue inhibitors of metalloproteinases) are a family
of four endogenous inhibitors that were originally characterized
by their ability to inhibit the MMPs (matrix metalloproteinases).
TIMPs have now been shown to also inhibit members of
two other related metalloproteinase families, the ADAMs (a
disintegrin and metalloproteinase) and the ADAMTSs (ADAM
with thrombospondin motifs). Specifically, TIMP-1 has been
shown to inhibit ADAM10 [1], whereas TIMP-2 has been shown
to inhibit ADAM12 [2] and ADAMTS-1 [3]; TIMP-3 has the
widest inhibitory activity among the TIMPs, since it has been
shown to inhibit ADAM10 [1], ADAM12 [2], ADAM17 [4],
ADAM28 [5], ADAM33 [6], ADAMTS-1 [3], ADAMTS-2 [7],
ADAMTS-4 [8,9] and ADAMTS-5 [9]. Not all ADAMs and
ADAMTSs are inhibited by the TIMPs; for example, none of
the four human TIMPs inhibits ADAM8 or ADAM9 [10].
TIMPs comprise two domains: the N-terminal inhibitory
domain and a C-terminal domain. The N-terminal inhibitory do-
main is a wedge-like structure that inhibits the MMPs by insertion
into the active site of the MMP. The crystal structure of the
TIMP-1–MMP-3 catalytic domain complex [11] shows that
the amino and carbonyl groups of Cys1 of TIMP-1 co-ordinate the
catalytic Zn2+ ion and that the Thr2 and Val4 side chains fit into
the S1′ and S3′ pockets of MMP-3 respectively. The importance
of the N-terminus of the TIMP has also been highlighted by
several mutagenesis [12–15] and chemical modification [16,17]
studies. These studies indicated that the N-terminal cysteine resi-
due is essential for MMP inhibitory activity. Mutation of this
residue to serine or blocking the N-terminal α-amino group by
the addition of an extra amino acid [15,17], acetylation [17] or
carbamylation [16] severely reduces inhibitory activity against
MMPs. The recent crystal structure of the ADAM17 catalytic
domain–N-TIMP-3 (N-terminal domain of TIMP-3) complex [18]
has confirmed that ADAM17 is also inhibited by TIMP-3 in a
similar manner as the MMPs, suggesting that the mechanism by
which TIMP-3 inhibits ADAMTSs is also similar.
We have reported previously, however, that two N-terminal
reactive-site mutants of N-TIMP-3, N-TIMP-3(T2G) and
[−1A]N-TIMP-3 (N-TIMP-3 with an extra alanine residue
appended to Cys1) which, as predicted from other studies [15–
17], are poor MMP inhibitors, still retain inhibitory activity
against ADAM17 [19]. This inhibition indicates that there are
subtle differences in TIMP inhibition of ADAMs compared with
that of the MMPs that are not immediately obvious from the
crystal structures. In the present paper, we report the testing
of these N-terminal reactive-site mutants of N-TIMP-3 for their
ability to inhibit the two primary aggrecanases ADAMTS-4 and
ADAMTS-5 based on their similar TIMP inhibitory profiles to
ADAM17 since they are potently inhibited only by TIMP-3.
Abbreviations used: ADAM, a disintegrin and metalloproteinase; ADAMTS, ADAM with thrombospondin motifs; CBB, Coomassie Brilliant Blue R-250;
DMBA, dimethylaminobenzaldehyde; DMEM, Dulbecco’s modified Eagle’s medium; DMMB, Dimethylmethylene Blue; Dpa, N-3-(2,4-dinitrophenyl)-L-2,3-
diaminopropionyl; GAG, glycosaminoglycan; GST, glutathione transferase; IGD, interglobular domain; IL-1α, interleukin-1α; Mca, (7-methoxycoumarin-4-
yl)acetyl; MMP, matrix metalloproteinase; N-TIMP, N-terminal domain of tissue inhibitor of metalloproteinases; OA, osteoarthritis; OSM, oncostatin M; TIMP,
tissue inhibitor of metalloproteinases.
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We have generated additional mutants with various lengths of
alanine extensions and with other amino acids at the −1 position
to determine whether these display further selectivity between the
two aggrecanases.
Aggrecan degradation in IL-1α (interleukin 1α)-stimulated
porcine articular cartilage explants, an ex vivo model of arthritis,
is inhibited by N-TIMP-3, but not by TIMP-1 or TIMP-2 [20],
suggesting that the ADAMTSs and not the MMPs are responsible
for the degradation of cartilage aggrecan. Furthermore, aggrecan
in the cartilage of ADAMTS-5-null mice was protected from
degradation when challenged with arthritis induced by surgical
joint destabilization [21], or with antigen-induced arthritis [22],
suggesting that, in mice, the primary aggrecanase in this disease
is ADAMTS-5. However, in cartilage from rheumatoid arthritis
and OA (osteoarthritis) patients, there is evidence that aggrecan
is degraded by both the ADAMTSs and MMPs; tissue sections
stain positive for neo-epitopes produced by both MMP and
ADAMTS activity [23]. Aggrecan fragments from both MMP-
and ADAMTS-mediated degradation have also been found in
OA joint cartilage and synovial fluid [24]. Degradation of the
other cartilage structural macromolecule type II collagen is
mediated primarily by the collagenases, which are members of
the MMP family [25]. Consequently, the relative contribution
of the ADAMTSs and the MMPs in the progression of human
disease remains unclear. We therefore applied our reactive-site
mutants of N-TIMP-3 to investigate the role of ADAMTS and
MMPs in IL-1α-induced pig or IL-1α/OSM (oncostatin M)-
induced human OA cartilage degradation.
EXPERIMENTAL
Materials
Restriction enzymes were from New England Biolabs.
The plasmid pGEX-4T1, Pfu DNA polymerase, GFX Gel
Band PCR Purification kit, GFX Microplasmid Purification
kit and glutathione–Sepharose 4B column material were
from GE Healthcare. Precision protein standards for
SDS/PAGE were from Bio-Rad Laboratories. Proteinase
inhibitor cocktail set II was purchased from Calbiochem.
Chloramine T, DMBA (dimethylaminobenzaldehyde), DMMB
(Dimethylmethylene Blue) and OSM were obtained from
Sigma–Aldrich. ADAM17 and the Mca-PLAQAV-Dpa-RSSSR
[where Mca is (7-methoxycoumarin-4-yl)acetyl and Dpa
is N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl] fluorigenic
substrate were from R&D Systems. The Mca-PLGL-Dpa-AR
fluorigenic substrate was supplied by Bachem. TIMP-1, TIMP-2,
N-TIMP-3, MMP-1C (catalytic domain of MMP-1), MMP-2,
MMP-3C (catalytic domain of MMP-3), ADAMTS-4-2 and
ADAMTS-5-4 were prepared as described previously [9,17,26–
30]. Purified IL-1α was a gift from Professor J. Saklatvala
(Kennedy Institute of Rheumatology, Imperial College London).
Anti-ARGSV antibody was a gift from Professor B. Caterson
(School of Biosciences, Cardiff University, Cardiff, U.K.).
Porcine metacarpophalangeal joints were supplied by Fresh
Tissue Supplies and dissected on-site within 24 h of slaughter.
Human cartilage was obtained from consenting OA patients
undergoing hip or knee joint replacement at Heatherwood and
Wexham Park Hospital (Slough, Berkshire, U.K.).
Construction of N-TIMP-3 mutants
The plasmid pET-42b-N-TIMP-3-His was used as the template for
mutagenesis by PCR as described in [19]. The common reverse
primer 5′-AAAAGCGGCCGCGTTACAACCCAGGTGATA-3′
(NotI restriction site in bold italics) was used in all mutagenesis
procedures. The forward primers used were: [−2A]N-TIMP-3,
5′-AAAACATATGGCAGCATGCACATGCTCGCCCAGC-3′;
[−3A]N-TIMP-3, 5′-AAAACATATGGCAGCAGCATGCACA-
TGCTCGCCCAGC-3′; [−5A]N-TIMP-3, 5′-AAAACATATG
GCAGCAGCAGCAGCATGCACATGCTCGCCCAGC-3′;
[−8A]N-TIMP-3, 5′-AAAACATATGGCAGCAGCAGCAGCA-
GCAGCAGCATGCACATGCTCGCCCAGC-3′; [−1G]N-
TIMP-3, 5′-AAAACATATGGGTTGCACATGCTCGCCCAGC-
3′; [−1M]N-TIMP-3, 5′-AAAACATATGATGTGCACATGCTC-
GCCCAGC-3′; [−1E]N-TIMP-3, 5′-AAAACATATGGAGTGC-
ACATGCTCGCCCAGC-3′ and [−1K]N-TIMP-3, 5′-AAAA-
CATATGAAGTGCACATGCTCGCCCAGC-3′ (codons for the
mutated amino acids are underlined and the NdeI restriction site
in bold italics).
Expression and purification of N-TIMP-3 and mutants
N-TIMP-3 and its mutants were expressed in Escherichia coli
BL-21(DE3) and purified by Ni2+-chelate chromatography as
described previously [9]. Additionally, endotoxin was removed
by including a wash step with 60% propan-2-ol and 6 M
guanidinium chloride, during column chromatography [31]. The
amount of endotoxin after purification was determined using the
Limulus amoebocyte lysate assay (Cambrex) to be less than 1
pg/pmol of N-TIMP-3. The level of endotoxin that stimulated
cartilage matrix degradation in porcine articular cartilage explants
was >1 ng/ml.
MMP and ADAM17 inhibition kinetics
The ability of N-TIMP-3 mutants to inhibit the MMPs and
ADAM17 was tested using the fluorigenic substrate Mca-
PLG∼L-Dpa-AR (∼ indicates the scissile bond) [32] for the
MMPs and Mca-PLA∼QAV-Dpa-RSSSR for ADAM17. The N-
TIMP-3 mutants were pre-incubated with MMP (1 nM MMP-
1C, 125 pM MMP-2, 500 pM MMP-3C) or 250 pM ADAM17
ectodomain for 1 h at 37 ◦C before residual activity was measured
by fluorescence increase (excitation 323 nm, emission 395 nm)
using 2 μM substrate. The data were fitted to the tight binding
inhibitor equation: v = [(E–I–k+[(E–I–k)2+4Ek] 12 )/(2E)], where
v is the velocity of the reaction, E is the enzyme concentration, I is
the initial inhibitor concentration, and k is the apparent inhibition
constant, using Prism (GraphPad Software).
Construction, expression and purification of gst-IGD-flag
The expression plasmid pGEX-4T1 containing the GST
(glutathione transferase) sequence fused with the IGD
(interglobular domain) of aggrecan (Tyr330–Gly457), with a C-
terminal FLAG (DYKDDDDK) sequence, cloned into the EcoRI
and XhoI cloning sites (Figure 1A). The plasmid was transformed
into E. coli BL-21(DE3) cells. Recombinant protein expression
was induced with IPTG (isopropyl β-D-thiogalactopyranoside)
(100 μM) overnight at 25 ◦C. Bacteria were harvested, washed
and mechanically disrupted with a French Press (five times
at 1500 psi, where 1 psi = 6.9 kPa). After centrifugation at
1500 g for 15 min, the supernatant containing gst-IGD-flag was
applied to a glutathione–Sepharose 4B column equilibrated
with 50 mM Tris/HCl (pH 8.0). The column was washed with
50 mM Tris/HCl (pH 8.0) and 0.5 M NaCl and eluted
with 10 mM reduced glutathione in 50 mM Tris/HCl (pH 8.0).
The eluted protein substrate was dialysed three times against 10
vol. of 50 mM Tris/HCl (pH 8.0) and 150 mM NaCl for 4 h at
4 ◦C and concentrated to an A280 of >2.5 using poly(ethylene
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Figure 1 Characterization of the gst-IGD-flag substrate
(A) Schematic representation of the gst-IGD-flag substrate and its products upon aggrecanase activity. The observed molecular masses are indicated in parentheses. (B) Time course of cleavage of
gst-IGD-flag by ADAMTS-5-4. gst-IGD-flag (17 μM) was incubated with recombinant ADAMTS-5-4 (500 pM) at 37◦C. At different time points (0–32 h), reactions were stopped and analysed by
SDS/PAGE (10 % acrylamide). The 17 kDa product band (arrow) also stained positive for the aggrecanase generated neo-epitope ARGSV. (C) The product was analysed by densitometry to calculate
the extent of cleavage, expressed as pixel volumes. (D and E) Cleavage of gst-IGD-flag by different amounts of enzyme ([E]). gst-IGD-flag (16 μM) substrate was incubated for 16 h at 37◦C with
increasing amounts of ADAMTS-5-4 (0–2 nM). M, molecular mass markers (size in kDa).
sulfate) membrane spin concentrators. The concentration of
intact substrate was determined to be approx. 34 μM. The yield
of substrate (approx. 20 mg of partially purified gst-IGD-flag per
litre of bacterial culture) was sufficient for over 2000 assays.
gst-IGD-flag aggrecanase assays
Equal volumes (5 μl) of 17 μM gst-IGD-flag and 1 nM
ADAMTS-4 which lacks the C-terminal spacer domain
(ADAMTS-4-2 [29]) or 0.5 nM ADAMTS-5 which lacks the
C-terminal cysteine-rich spacer and thrombospondin domains
(ADAMTS-5-4 [30]) were incubated at 37 ◦C for the indicated
period of time. Inhibitor, if used, was pre-incubated with
the ADAMTS enzyme (total volume 5 μl) at 37 ◦C for 1 h
before addition of 5 μl of the substrate for 1 h. The reactions
were stopped by addition of an equal volume (10 μl) of 2×
SDS/PAGE sample buffer containing 10 mM EDTA. SDS/PAGE
(10% acrylamide) was run under reducing conditions using
a modification of the ammediol/glycine/HCl buffer system
described by Wyckoff et al. [33]. Following staining with CBB
(Coomassie Brilliant Blue R-250), the amount of product was
determined by densitometric quantification of the 17 kDa band
using the GS-710 scanning densitometer (Bio-Rad Laboratories)
and analysed using the 1D Phoretix Software (Nonlinear
Dynamics). Under conditions where substrate cleavage was linear,
the amount of substrate cleaved is directly related to the velocity
of the reaction. For inhibition kinetics, the data were fitted to the
same tight binding equation as in the MMP inhibition kinetics.
Cartilage explant cultures
Porcine articular cartilage explants were prepared as described
previously [20]. Explanted human cartilage pieces (approx.
5 mm × 5 mm × 2.5 mm) from either the femoral head or the
knee were rested overnight in DMEM (Dulbecco’s modified
Eagle’s medium) with 20% (v/v) fetal bovine serum before being
washed twice with DMEM without serum. Each cartilage piece
was placed in one well of a round-bottomed 96-well plate with
200 μl of serum-free DMEM with or without IL-1α (10 ng/ml)
and OSM (50 ng/ml), together with various concentrations of each
TIMP. Each treatment was prepared in triplicate. After 3 days, the
conditioned media were harvested and stored at −20 ◦C until use.
For longer-term culture of porcine articular cartilage, the media
were replaced every 4 days and the harvested media were stored
as above.
Analysis of cartilage degradation
GAG (glycosaminoglycan) release into the culture medium was
determined as described previously [20]. Hydroxyproline released
into the culture medium was determined using a modification of
the assay as described by Bergman and Loxley [34].
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Molecular modelling with AutoDock 4.2
Molecular docking of N-TIMP-3 and the mutants on to the three-
dimensional X-ray structure of the catalytic domain of MMP-1
and ADAMTS-5 was carried out using the AutoDock software
package (version 4.2) as implemented through the graphical
user interface AutoDockTools (ADT 1.5.4) [35]. The structures
used were from the N-TIMP-1–MMP-1 complex (PDB code
2J0T [36]), the N-TIMP-3-ADAM17 complex (PDB code 3CKI
[18]), ADAM17 (PDB code 3G42 [37]), ADAMTS-4 (PDB code
2RJP [38]) and ADAMTS-5 (PDB code 2RJQ [38]). To create
the initial co-ordinates for docking studies, the water molecules
were removed from the crystal structures and excluded from the
calculations. The non-catalytic ZnCl2 found in the ADAMTS-5
structure was also removed. Hydrogen atoms were added and
Gasteiger charges computed. For the catalytic zinc, the formal
charge of +2 and van der Waals radius of 0.87 Å (1 Å = 0.1 nm)
were used, as suggested by Hu and Shelver [39]. To minimize
computation time, the only bonds allowed to rotate were in
mutated residues of the TIMP. The docking area was defined
by a box, centred on the TIMP-binding position above the metal-
loproteinase. Grids points of 100 × 100 × 100 with 0.5 Å spacing
were calculated around the docking area for all the ligand atom
types using AutoGrid4. A total of 200 separate docking calcu-
lations were performed for each N-TIMP. Each docking
calculation consisted of 2500000 energy evaluations using the
Lamarckian genetic algorithm local search over 27000 genera-
tions. A mutation rate of 0.02 and a crossover rate of 0.8 were
used to generate new docking trials for subsequent generations.
The results of the docking experiments were visualized using
PyMOL (DeLano Scientific; http://www.pymol.org/).
RESULTS
Aggrecanase assay using the gst-IGD-flag substrate
The gst-IGD-flag substrate purified from the soluble extract of
the E. coli contained a considerable amount of lower-molecular-
mass products after purification (Figure 1B, lane 1). Either the
GST tag or the FLAG tag was associated with these bands,
indicating degradation (results not shown). The degradation was
not prevented by the addition of protease inhibitors (results not
shown). Further purification using ion-exchange and size-
exclusion chromatography did not separate the degradation
products from the intact substrate under native conditions (results
not shown). However, the intact substrate accounted for over 70%
of the CBB-stainable protein bands (Figure 1B, lane 2), and the
expected product after ADAMTS cleavage (Figure 1B, arrow)
was distinguishable from the degradation products. The apparent
molecular masses of the intact substrate and cleavage products
were 52, 35 and 17 kDa respectively. These were higher than
the calculated molecular masses (Figure 1A). The 17 kDa band
reacted with the neo-epitope antibody which recognizes the newly
generated N-terminal A374RGS377 of the aggrecan core protein,
indicating that it is an authentic C-terminal fragment generated
by aggrecanase activity (Figure 1B).
The linear range of gst-IGD-flag cleavage was determined by
incubating 17 μM gst-IGD-flag with 0.5 nM ADAMTS-5-4 for
up to 32 h at 37 ◦C (Figure 1B). Densitometric analysis of the
products after SDS/PAGE separation and CBB-staining indicated
that cleavage was linear up to 400000 pixel volumes, equivalent
to incubation with 0.5 nM ADAMTS-5-4 for 20 h (Figure 1C).
The enzyme concentration-dependence of substrate cleavage was
determined by incubating gst-IGD-flag with increasing amounts
of ADAMTS-5-4 (0–2.5 nM) for 20 h at 37 ◦C before visualization
Figure 2 The K i (app) of N-TIMP-3 mutants for ADAMTS-4-2 and
ADAMTS-5-4
N-TIMP-3 or the mutants (0–1 μM) were incubated with ADAMTS-4-2 [1 nM (A and C)] or
ADAMTS-5-4 [500 pM, (B and D)] for 1 h at 37◦C, before the addition of gst-IGD-flag (17 μM).
After 16 h at 37◦C, SDS/PAGE and densitometric analysis of the 17 kDa product band was used
to determine the percentage of residual activity. Data were fitted to the tight binding equation to
obtain the K i (app).
by CBB staining (Figure 1D). Cleavage was linear up to 0.5 nM
enzyme (Figure 1E).
Inhibition of aggrecanases by reactive-site mutants of N-TIMP-3
Using the gst-IGD-flag assay, we tested the ability of N-TIMP-
3(T2G) and [−1A]N-TIMP-3 to inhibit the aggrecanases. The
remaining activity after inhibition was plotted as percentage
activity against inhibitor concentration in Figures 2(A) and 2(B)
for ADAMTS-4-2 and ADAMTS-5-2 respectively, and the data
were fitted to the tight binding inhibition equation to obtain the K i
(app) values shown in Table 1, with the S.E.M. values representing
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Table 1 K i (app) of N-terminal reactive-site mutants for MMP-1C, MMP-2, MMP-3C, ADAMTS-4-2 and ADAMTS-5-4
K i (app) (nM)
Inhibitor MMP-1C MMP-2 MMP-3C ADAM17 ADAMTS-4-2 ADAMTS-5-4
N-TIMP-3 1.7 +− 0.2 2.7 +− 0.3 53.6 +− 5.4 13.7 +− 0.2 1.8 +− 0.2 0.5 +− 0.1
N-TIMP-3(T2G) >1000 >1000 >1000 35.6 +− 1.9 18.3 +− 0.1 1.5 +− 0.1
[−1A]N-TIMP-3 800 970 >1000 33.9 +− 2.8 22.2 +− 0.1 1.7 +− 0.1
the goodness of fit. The mutants retained inhibitory activity for
ADAMTS, with K i (app) values between 18 and 30 nM for
ADAMTS-4-2 and approx. 1.5 nM for ADAMTS-5-4. N-TIMP-
3 shows co-operativity in its inhibition of ADAM17 with a Hill
coefficient, h, for N-TIMP-3 inhibition of ADAM17 of 3.59 [19],
but the inhibition curves reported in the present paper fitted the
equation for tight binding non-co-operative inhibition, reflecting
an h value of 1. All of the N-terminal reactive-site mutants tested
show selective inhibition for the ADAMTS enzymes over the
MMPs.
Effect of extending the number of alanine residues appended to the
N-terminus on the inhibition of ADAM17 and the aggrecanases
The alanine-extension mutants [−2A]N-TIMP-3, [−3A]N-
TIMP-3, [−5A]N-TIMP-3 and [−8A]N-TIMP-3 with two, three,
five and eight additional alanine residues at the N-terminus
respectively were tested for their ability to inhibit ADAMTS-4
and ADAMTS-5 (Figures 2C and 2D respectively). These mutants
were also tested against MMP-1C, MMP-2, MMP-3C and
ADAM17. The results are summarized in Table 2. All of the
alanine-extension mutants were poor MMP inhibitors, with less
than 50% inhibition observed at the highest concentration tested
(1 μM). The [−2A]N-TIMP-3 remained a potent inhibitor for
ADAMTS-5 [K i (app) = 1.8 nM], but was weaker for ADAMTS-
4 [K i (app) = 35.9 nM] and ADAM17 [K i (app) = 65.3 nM]. With
three additional alanine residues, the apparent inhibition constants
for ADAM17, ADAMTS-4 and ADAMTS-5 were approx. 100-
fold worse compared with that of the wild-type inhibitor. The K i
(app) for ADAM17 was 239 nM, similar to that for ADAMTS-4.
The inhibitory ability of the [−5A]N-TIMP-3 and the [−8A]N-
TIMP-3 mutants decreased further, where the [−8A]N-TIMP-
3 showed no significant inhibition at the highest concentration
tested (1 μM). N-terminal sequence analysis indicated that all of
these mutants started with the expected alanine residue.
Effect of changing the amino acid at position [−1] on the inhibition
of ADAMTS-4 and ADAMTS-5
To investigate the properties of the enzyme pocket that
accommodates the N-terminus, the mutants [−1G]N-TIMP-3,
[−1E]N-TIMP-3, [−1M]N-TIMP-3 and [−1K]N-TIMP-3
were generated and their ability to inhibit MMPs, ADAM17,
ADAMTS-4 and ADAMTS-5 were tested. N-terminal sequencing
indicated that the N-termini of these mutants were
differently processed by E. coli. The N-terminal residues of
[−1E]N-TIMP-3, [−1M]N-TIMP-3 and [−1K]N-TIMP-3 were
methionine, making them [−ME]N-TIMP-3, [−MM]N-TIMP-
3 and [−MK]N-TIMP-3. The mutant [−1G]N-TIMP-3 did not
return a sequence, suggesting that the N-terminus was chemically
modified, probably by N-acetylation (henceforth [−xG]N-TIMP-
3). As the [−2A]N-TIMP-3 mutant was still active against the
ADAMTSs, the K i (app) values of these mutants for the various
metalloproteinases were determined.
Figure 3 Dose-dependent inhibition of GAG release upon IL-1α stimulation
in porcine articular cartilage by N-TIMP-3 reactive-site mutants
Porcine articular cartilage explants were stimulated with IL-1α (10 ng/ml) for 3 days with the
various TIMPs at the concentrations indicated (0.01, 0.1 and 1 μM). GAG released in
the medium was measured by DMMB. n = 3 for each treatment.
As summarized in Table 3, all of the mutants were poor
MMP inhibitors, with less than 50% inhibition at the highest
concentration tested (1 μM), apart from [−MK]N-TIMP-3, which
inhibited MMP-1 and MMP-2 with K i (app) values of 0.5 and
0.75 μM respectively. On the other hand, [−MM]N-TIMP-3
inhibited ADAMTS-4, ADAMTS-5 and ADAM17 with K i (app)
values of 75, 69 and 153 nM respectively. The other [−1] mutants
were weaker inhibitors of these enzymes.
Inhibition of porcine cartilage degradation by reactive-site mutants
of N-TIMP-3
The aggrecanase-selective mutants N-TIMP-3(T2G), [−1A]N-
TIMP-3 and [−2A]N-TIMP-3 were tested in the IL-1α-stimulated
porcine articular cartilage explant model of cartilage degradation.
As reported previously [20], upon stimulation with IL-1α, there
was a 5-fold increase in GAG release from explanted porcine
articular cartilage, which was not inhibited by TIMP-1 or TIMP-2,
but was dose-dependently inhibited by N-TIMP-3. Additionally,
all three of the N-TIMP-3 mutants tested were able to inhibit
this release dose-dependently, although they were slightly weaker
than N-TIMP-3 (Figure 3).
Collagen degradation of IL-1α-stimulated cartilage was not
inhibited by aggrecanase-selective TIMP-3 mutants
Upon stimulation with IL-1, collagen degradation in porcine
cartilage mediated by MMPs occurs after 21 days [40]. The
cartilage-stimulation experiments were therefore extended for a
longer time period at a single dose of 100 nM of the various
TIMPs to determine the effects of the mutants on aggrecan and
collagen catabolism.
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Table 2 K i (app) of N-terminal alanine-extension mutants for MMP-1C, MMP-2, MMP-3C, ADAMTS-4-2 and ADAMTS-5-4
K i (app) (nM)
Inhibitor MMP-1C MMP-2 MMP-3C ADAM17 ADAMTS-4-2 ADAMTS-5-4
[−1A]N-TIMP-3 800 970 >1000 33.9 +− 2.8 22.2 +− 0.1 1.7 +− 0.1
[−2A]N-TIMP-3 >1000 790 >1000 65.3 +− 5.2 35.9 +− 8.4 1.8 +− 0.9
[−3A]N-TIMP-3 >1000 >1000 >1000 239 173.7 87.6
[−5A]N-TIMP-3 >1000 >1000 >1000 843 385 593
[−8A]N-TIMP-3 >1000 >1000 >1000 >1000 >1000 >1000
Table 3 K i (app) of position [−1] mutants for MMP-1C, MMP-2, MMP-3C, ADAMTS-4-2 and ADAMTS-5-4
K i (app) (nM)
Inhibitor MMP-1C MMP-2 MMP-3C ADAM17 ADAMTS-4-2 ADAMTS-5-4
[−1A]N-TIMP-3 800 970 >1000 33.9 +− 2.8 22.2 +− 0.1 1.7 +− 0.1
[−xG]N-TIMP-3 >1000 >1000 >1000 465 107 118
[−ME]N-TIMP-3 >1000 >1000 >1000 529 326 327
[−MM]N-TIMP-3 >1000 >1000 >1000 153 75.7 69.4
[−MK]N-TIMP-3 500 750 >1000 325 280 217
As in the previous experiment, TIMP-1 and TIMP-2 did not
affect the amount of GAG release from the cartilage upon IL-1α
stimulation (Figure 4A). There was no significant difference in
GAG release between stimulated cartilage explants in the presence
of N-TIMP-3 and the unstimulated cartilage explants, indicating
that TIMP-3 is an effective inhibitor of aggrecanases. However,
there was a gradual loss of aggrecan from the tissue even without
IL-1α stimulation, and by the end of 38 days, this equated to the
loss of approx. 45% of the total GAG content. The N-TIMP-3
mutants significantly reduced the release of GAG at the early time
points, compared with TIMP-1 and TIMP-2. However, there was
a slow gradual loss of aggrecan above that observed for N-TIMP-
3. This equated to approx. 85% of the total GAG content lost
after 38 days.
Collagen degradation as measured by hydroxyproline release
into the medium started at day 21 and rapidly progressed
thereafter: after 35–38 days, the cartilage tissue was almost
completely dissolved. TIMP-1, TIMP-2 and N-TIMP-3 inhibited
collagen degradation, whereas the aggrecanase-selective N-
TIMP-3 mutants were unable to inhibit collagen degradation
(Figure 4B).
Inhibition of aggrecan degradation but not collagen degradation in
human cartilage explants stimulated by IL-1α and OSM by
N-TIMP-3 mutants
Stimulation of cartilage from human OA patients by IL-1α alone
was insufficient to cause aggrecan degradation in 3 days (results
not shown), but, in combination with OSM, there was a 2–3-fold
increase in GAG release (Figure 5A), which represented approx.
3% of total GAG in the tissue. Cartilage from one knee joint
was used to test the effects of the different doses of inhibitor.
TIMP-1 unexpectedly showed dose-dependent inhibition of GAG
release in this tissue, in contrast with porcine cartilage. TIMP-2,
however, showed no inhibition of GAG release, making it unlikely
that an MMP was involved. N-TIMP-3 was the most potent
inhibitor of stimulated GAG release, with 0.1 μM completely
inhibiting it. The three reactive-site mutants N-TIMP-3(T2G),
[−1A]N-TIMP-3 and [−2A]N-TIMP-3 inhibited GAG release
dose-dependently, although they were not as potent as N-TIMP-
3. Within 3 days of culture, there was no stimulatory increase in
Figure 4 Effects of the N-TIMP-3 mutants on aggrecan and collagen
degradation in porcine articular cartilage under long-term stimulation with
IL-1α
Porcine articular cartilage explants were stimulated with IL-1α (10 ng/ml) with the various
TIMPs at 0.1 μM for 38 days. The amount of GAG and hydroxyproline (Hypro) released into
the medium was measured using the DMMB and DMBA assay respectively. The cumulative
amounts of GAG (A) and hydroxyproline (B) loss against time were plotted. n = 3 for each
treatment.
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Figure 5 Inhibition of GAG release but not hydroxyproline release of explanted human articular cartilage stimulated with IL-1α
Cartilage from the knee of an OA patient was stimulated with IL-1α (10 ng/ml)+OSM (50 ng/ml) and the various TIMPs (0.01, 0.1 and 1 μM concentrations) for 3 days. GAG (A) and hydroxyproline
(Hypro) (B) released into the medium were taken as measures of cartilage degradation. n = 3 for each treatment. Cartilage samples from the hips of five OA patients (the previous and four additional)
were treated with IL-1α (10 ng/ml) and the various TIMPs at a concentration of 100 nM. Data from the different patients were normalized by taking the amount of (C) GAG released upon stimulation
as 100 and (D) hydroxyproline (Hypro) released without stimulation as 100, shown as means +− S.D., n = 3 for each patient; *P < 0.03.
collagen degradation, even when the tissue was treated with IL-1α
and OSM (Figure 5B). The collagen degraded in 3 days of culture
represented approx. 1.5% of the total collagen in the tissue. This
suggests that the collagenolytic MMPs are already activated in OA
cartilage. The hydroxyproline release from the OA cartilage was
dose-dependently inhibited by TIMP-1, TIMP-2 and N-TIMP-3,
but the aggrecanase-selective N-TIMP-3 mutants had no effect on
the collagen degradation (Figure 5B).
The experiments were repeated on cartilage obtained from the
hips of four other patients using a single concentration of 0.1 μM
of the respective TIMPs (n = 5, including the previous patient).
The GAG and hydroxyproline released upon stimulation without
TIMP was normalized to a value of 100 in order to compare
the different patients (Figure 5C and 5D). At a concentration
of 0.1 μM, TIMP-1 showed a 50% inhibition of GAG release,
whereas N-TIMP-3 inhibited GAG release to below that of control
levels. TIMP-2 had no effect on GAG release. The three N-TIMP-
3 mutants inhibited GAG release to control levels, but did not
have any effect on collagen degradation, whereas the three wild-
type TIMPs inhibited collagen degradation approx. 50% at a
concentration of 0.1 μM.
Docking of N-TIMP-3 and modelled mutants to MMP-1, ADAM17,
ADAMTS-4 and ADAMTS-5
In the absence of a crystal structure, we carried out molecular
docking experiments to attempt to explain the inhibitory
capabilities of the various mutants of TIMP-3. Docking of N-
TIMP-3 with the ADAM17 component from the N-TIMP-3–
ADAM17 complex (PDB code 3CKI) was first performed to
validate the docking method. All 200 docking runs returned
structures that fitted in the active-site cleft of the enzyme. The
same N-TIMP-3 structure docked with a different ADAM17
structure (PDB code 3G42) returned 52 active-site fits. The
positions of residues Lys315 and Met345, which are located on the
active-site cleft of ADAM17, differ between the two ADAM17
structures. In the ADAM17 (PDB code 3G42) structure, they
create a more restricted active-site cleft, which may explain
the fewer active-site fits in this docking experiment. The same
N-TIMP-3 structure docked into MMP-1, ADAMTS-4 and
ADAMTS-5 returned 69, 2 and 27 active-site fits respectively.
The modelled complex of N-TIMP-3 with the MMP-1 model
was similar to the experimentally determined structure of the N-
TIMP-1–MMP-1 complex [36]. The fit of N-TIMP-3 into the
active site of ADAMTS-4 and ADAMTS-5, however, differed
from those with MMP-1 and ADAM17: the catalytic Zn2+ ion
was still chelated by the N-terminal cysteine residue of the TIMP,
but the TIMP was tilted towards the prime side of the active site
so that Phe34 of the TIMP that normally interacts with Tyr351Val352
of ADAM17 was not in contact with either ADAMTS, creating
a water-accessible gap between the TIMP-3 and the ADAMTS
components. The interaction of the bulky Arg84 of TIMP-3 with
the loop G323VST326 in ADAMTS-4 or G372HHS375 of ADAMTS-
5 probably prevented TIMP-3 binding in the same way as
in previously characterized TIMP–metalloproteinase complexes.
Mutation of all of these residues on both molecules to alanine
in silico generated complexes that are more similar to the cano-
nical TIMP–metalloproteinase interaction, supporting the above
possibility.
The model of [−1A]N-TIMP-3 was created by the addition
of an alanine residue at the N-terminus of the N-TIMP-3 crystal
structure, with the alanine residue being allowed to rotate in the
docking experiments. When docked with MMP-1, 29 structures
in the active site were obtained containing TIMP-3 docked in the
MMP-1 active site. However, to accommodate the extra alanine
residue, the TIMP was tilted in such a manner that Phe34 was
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Figure 6 In silico models of N-TIMP-3 and [−1A]N-TIMP-3 with ADAM17, MMP-1, ADAMTS-4 and ADAMTS-5
Computer-simulated lowest free energy ranked models of complexes of N-TIMP-3 (salmon ribbon) or [−1A]N-TIMP-3 (blue ribbon) with MMP-1 (A), ADAM17 (B), ADAMTS-4 (C) or ADAMTS-5
(D) are shown. The catalytic Zn2+ ion is shown in magenta, water-accessible enzyme surfaces are grey and regions which interact only with N-TIMP-3, [−1A]N-TIMP-3 or with both are in salmon,
blue and green respectively. Phe34 and the N-terminal extra alanine residues are shown with sticks. In the [−1A]N-TIMP-3 complexes with MMP-1 and ADAM17, the TIMP molecule is tilted and
the interaction of Phe34 of the inhibitor with the enzymes are lost. Both N-TIMP-3 and [−1A]N-TIMP-3 are bound to ADAMTS-4 and ADAMTS-5 in a similar tilted manner. Residues which make the
deeper active-site clefts of ADAM17 (Met345), ADAMTS-4 (G322VST325) and ADAMTS-5 (G372HHS375) that interact with the TIMP and are not present in MMP-1 are highlighted in red.
not in contact with the enzyme, and the TIMP leant to one side
of the active-site cleft (Figure 6A). When [−1A]N-TIMP-3 was
docked with ADAM17 (PDB code 3CKI), 108 structures were
returned containing TIMP-3 in the active-site cleft. The TIMP
molecule was tilted towards the prime side of the active site,
such that Phe34 of the TIMP was no longer in contact with the
enzyme, as in the models of N-TIMP-3 docked into ADAMTS-4
and ADAMTS-5 (Figure 6B). In this model, however, the access
of the catalytic Zn2+ ion to water is blocked by the side chain of
the alanine residue. Docking [−1A]N-TIMP-3 with ADAMTS-4
and ADAMTS-5 produced 4 and 28 models in which TIMP-3
is in contact with the active site respectively. These were very
similar to the corresponding complexes generated with N-TIMP-
3, except that access of the catalytic Zn2+ ion to water was blocked
by the NH2 group of the alanine (Figures 6C and 6D). The models
of [−1A]N-TIMP-3 had additional interactions with the deeper
active-site clefts of ADAM17, ADAMTS-4 and ADAMTS-5 that
were not present in the MMP-1 complexes. These were with
Met345 in ADAM17, the loop G323VST326 in ADAMTS-4 and
G372HHS375 in ADAMTS-5 (highlighted in Figure 6).
DISCUSSION
Using the newly developed gst-IGD-flag substrate, we
demonstrate that the N-terminal mutants of N-TIMP-3 that have
essentially lost their MMP-inhibitory activities, N-TIMP-3(T2G)
and [−1A]N-TIMP-3, retain their ability to inhibit ADAMTS-4
and ADAMTS-5. Furthermore, the [−2A]N-TIMP-3 mutant also
retained strong affinity with ADAMTS-5, but has a lower affinity
for ADAMTS-4 and ADAM17.
The ability of these three mutants to dose-dependently inhibit
aggrecan degradation in the IL-1α-stimulated model of porcine
cartilage degradation reinforces our previous observations that the
enzymes involved in the degradation of aggrecan in this system are
from the ADAMTS family and are not MMPs [20]. There was no
inhibition of collagen degradation when the N-TIMP-3 mutants
were tested in the long-term IL-1α-stimulated porcine articular
cartilage. As theTIMP-3 mutants used in the present study lack
the ability to inhibit the MMPs, they were not expected to exhibit a
direct effect on MMP-mediated collagen degradation, confirming
that the selectivity of these N-TIMP-3 mutants was maintained
ex vivo. Pratta et al. [41] reported that, in IL-1α-induced bovine
nasal cartilage degradation, the blocking of aggrecan degradation
by an ADAMTS-selective chemical inhibitor resulted in inhibition
of collagen degradation. The discrepancy between the two studies
may be due to different levels of aggrecan protection: in the
present study, a slower persistent loss of aggrecan was observed in
the explant cultures when the mutants were used at a concentration
of 0.1 μM above the amount observed in the control and N-TIMP-
3-treated explants, whereas aggrecan degradation was almost
completely blocked in the study by Pratta et al. [41]. The amount
of intact aggrecan left in the explants therefore may not have
been sufficient to influence collagen degradation. Interestingly,
mice deficient in MMP-13 are also protected in an animal model
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of OA [42], indicating that inhibition of MMP-13 is also an
effective cartilage protectant. The inhibition of both aggrecanases
and collagenases, as shown with 0.1 μM wild-type TIMP-3, may
be an effective way to protect cartilage from degradation during
the progression of OA.
The N-TIMP-3 reactive-site mutants are able to inhibit IL-
1α with OSM-stimulated GAG release from human cartilage
explants in culture. This inhibition, however, had no effect on
the amount of collagen degradation detected, indicating that,
by the stage when joint-replacement surgery was required,
protection of aggrecan degradation had little effect on the
outcome of collagen degradation. Furthermore, hydroxyproline
release was fully activated in human OA cartilage without IL-
1α and OSM treatment and it was dose-dependently inhibited by
TIMP-1, TIMP-2 and TIMP-3, suggesting that the collagenolytic
MMPs were fully active at this stage. Further studies using our
ADAMTS-selective mutants in combination with TIMP-2 and
TIMP-3 will enable us to dissect the relative contributions of
the ADAMTSs and the MMPs during the progression of joint
cartilage degradation and the benefits of targeting either protease
at different stages of the disease.
On the basis of the crystal structure of ADAM17–N-TIMP-
3 complex, it was considered that there would not be sufficient
space in the active site of the enzyme to accommodate TIMPs with
one or two additional amino acids at the N-terminus. However,
our enzyme-inhibition studies described in the present paper have
shown that up to two alanine residues can be accommodated.
The in silico docking experiments performed indicate that the
[−1A]N-TIMP-3 mutant is most likely to be tilted so that Phe34
of the TIMP is no longer in contact with the enzyme, while
still blocking the access of the catalytic Zn2+ ion to the water
molecule required for peptide hydrolysis. Our in vitro inhibition
data suggest that, with MMP-1, this leads to a large loss of
binding energy which renders the TIMP inactive, but this is not
the case in ADAM17, ADAMTS-4 and ADAMTS-5. Additional
interactions with Met345 in ADAM17, G322VST325 in ADAMTS-4
and G372HHS375 in ADAMTS-5 may compensate for the loss of
binding energy associated with the loss of interactions involving
Phe34. The amino acids within the TIMP molecule that are
likely to be in contact with these extended loops include the
residues around Leu94 and Arg84, which were identified by Lee
et al. [43,44] as being important in ADAM17 inhibition. In
addition, comparison of the crystal structures of ADAMTS-4 in
the presence and absence of a synthetic inhibitor, and those of
ADAMTS-5, showed that the loops G322VST325 and G372HHS375,
designated the S2′ loop by Mosyak et al. [38], are able to adopt
at least two different conformations. Similarly, ADAM17 has
been shown to have a more flexible active site than MMP-2 upon
binding to a non-competitive inhibitor [45]. The flexible nature
of these active sites may allow TIMP-3 with one or two extra
alanine residues at the N-terminus to still form tight enzyme–
inhibitor complexes. Further structural studies of [−1A]N-TIMP-
3 and the [−2A]N-TIMP-3 in complex with these enzymes will
be required to validate these docking predictions, whereas the
Leu94 and Arg84 residues may provide a further avenue in TIMP
engineering to obtain TIMPs capable of differentiating between
the two aggrecanases.
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